Key result
Pulmonary vasodilators decreased mortality compared to control treatment in pediatric patients with pulmonary hypertension.
Why the study?
The study was conducted to evaluate the efficacy and safety of pulmonary vasodilators in pediatric pulmonary hypertension patients.
Do pulmonary vasodilators reduce mortality and improve hemodynamics in pediatric patients with pulmonary hypertension?
Meta-Analysis (n=719)
Double-blind
Randomized
Yes
Do pulmonary vasodilators reduce mortality and improve hemodynamics in pediatric patients with pulmonary hypertension?
Pulmonary vasodilators significantly reduce mortality and improve respiratory and hemodynamic parameters in pediatric patients with pulmonary hypertension without increasing adverse events.
Answers are grounded in this paper and cite their sources.
Supports comparable safety across pulmonary vasodilators in pediatric PH; extends pooled evidence for individualized therapy selection.
Background: We performed a meta-analysis to evaluate the efficacy and safety of pulmonary vasodilators in pediatric pulmonary hypertension (PH) patients. Methods: We searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to May 2020, and conducted a subgroup analysis for pulmonary vasodilators or underlying disease. Results: Fifteen studies with 719 pediatric PH patients were included in the meta-analysis. Adverse events did not differ (p = 0.11, I2 = 15%) between the pulmonary vasodilators group and the control group, neither in the subgroups. In total, compared with the control group treatment, pulmonary vasodilators significantly decreased the mortality (p = 0.002), mean pulmonary artery pressure (mPAP, p = 0.02), and mechanical ventilation duration (p = 0.03), also improved the oxygenation index (OI, p = 0.01). In the persistent pulmonary hypertension of the newborn (PPHN) subgroup, phosphodiesterase type 5 inhibitors (PDE5i) significantly reduced mortality (p = 0.03), OI (p = 0.007) and mechanical ventilation duration (p = 0.004). Administration of endothelin receptor antagonists (ERAs) improved OI (p = 0.04) and mechanical ventilation duration (p < 0.00001) in PPHN. We also found that in the pediatric pulmonary arterial hypertension (PPAH) subgroup, mPAP was pronouncedly declined with ERAs (p = 0.006). Systolic pulmonary artery pressure (sPAP, p < 0.0001) and pulmonary arterial/aortic pressure (PA/AO, p < 0.00001) were significantly relieved with PDE5i, partial pressure of arterial oxygen (PaO2) was improved with prostacyclin in postoperative PH (POPH) subgroup (p = 0.001). Compared with the control group, pulmonary vasodilators could significantly decrease PA/AO pressure (p < 0.00001) and OI (p < 0.00001) in the short-term (duration <7 days) follow-up subgroup, improve mPAP (p = 0.03) and PaO2 (p = 0.01) in the mid-term (7–30 days) follow-up subgroup, also decrease mortality, mPAP (p = 0.0001), PA/AO pressure (p = 0.0007), duration of mechanical ventilation (p = 0.004), and ICU stay (p < 0.00001) in the long-term follow subgroup (>30 days). Conclusion: Pulmonary vasodilators decrease the mortality in pediatric PH patients, improve the respiratory and hemodynamic parameters, reduce the mechanical ventilation duration.
No takes yet. Share an insight, caveat, or question.
Shu et al. (2021) conducted a meta-analysis in Pediatric Pulmonary Hypertension (PH) (n=719). Pulmonary vasodilators (PDE5i, ERAs, PGI2) vs. Placebo or no treatment was evaluated on Mortality (RR 0.20, 95% CI 0.07-0.56, p=0.002). Pulmonary vasodilators decreased mortality compared to control treatment in pediatric patients with pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: